Introduction
It is estimated that out of the 100,000 or more species of mushrooms worldwide, more
than 100 are toxic. In the United States, the National Poison Data System reported
133,700 cases of mushroom exposure from 1999 to 2016, and 6136 cases in 2017.1, 2
Identifying the specific mushroom species involved is mandatory because specific treatment
exists for some mushroom poisoning. A recent algorithm to group the multiple species
and syndromes of mushroom poisoning into 6 presenting syndromes has been proposed
by White et al., depending on the clinical presentation.
3
Among severe mushroom intoxications, amatoxin syndrome accounts for 68% to 89% of
fatalities.
1
Mushroom poisoning usually causes gastroenteritis prodrome. Hepatotoxicity is rare
but is associated with a limited group of mushrooms. Renal failure can be due to severe
dehydration or to specific toxin damage. Early syndromes (onset of nausea and vomiting
in <6 hours) are usually associated with a good prognosis, whereas delayed syndromes
carry risk of organ failure, with the liver and kidney as the key organs of concern.
Herein, we present 2 cases of hepato-nephritis after mushroom ingestion in a married
couple, with a review of mushroom poisoning, toxidromes, diagnosis, and treatment.
Case Presentation
A 61-year-old woman and her 63-year-old husband presented to the emergency department
with identical symptoms evolving for several hours. They had gone for walk during
October in a French forest in Normandy, where they picked mushrooms that they identified
as King bolete (Boletus edulis or Cep of Bordeaux). Mushrooms were cooked the day
that they were picked, and eaten the next day in the evening.
Past medical history included diabetes, hypertension, and arrythmia for the wife,
and hypertension, diabetes, and myocardial infarction for the husband. They described
severe diarrhea (10 stools per day), nausea, and vomiting occurring 10 hours after
eating the mushrooms that they had picked and cooked. They went to the emergency department
because of the severity of the symptoms around 20 hours after the ingestion. Blood
pressure was 95/60 mm Hg for the wife, with a conserved diuresis, and 117/71 mm Hg
for the husband, associated with anuria. Physical examination was similar in both
patients, with a poor skin turgor. The abdomens were soft, without distension, rebound,
tenderness, or guarding, and the remainder of the general examination results were
normal. Laboratory results are presented in Table 1 for the 2 patients. Both patients
presented with acute kidney failure, which was complicated for the husband by metabolic
acidosis and hyperkalemia. Rhabdomyolysis was ruled out by normal creatine phosphokinase
levels. Urine dipsticks were negative for proteinuria. Renal ultrasound findings were
normal. Electrocardiograms showed no conduction abnormality, but peaked T waves for
the husband.
Table 1
Laboratory results on admission
Test
Wife
Husband
Reference range
Serum creatinine (mg/dl)
2.2
2.2
0.6–1.2
Blood urea nitrogen (mg/dl)
92
46.6
7–20
Potassium (mEq)
4.1
7
3.5–5
Bicarbonates (mEq)
15.5
10
24–30
Hemoglobin (g/dl)
11
13.5
13.5–18
Bilirubin (mg/dl)
8
16
1–10
Aspartate aminotransferase (U/l)
289
173
5–35
Alanine aminotransferase (U/l)
140
150
5–35
Alkaline phosphatase (U/l)
117
64
30–105
γ-Glutamyltransferase (U/l)
649
439
5–55
Prothrombin time (%)
81
56
70–100
Creatine phosphokinase (U/l)
36
133
30–200
In the present cases, renal failure was the prominent feature, which is unusual in
mushroom poisoning. The onset of symptoms was too early to fit an orellanine syndrome.
Clinical presentation fitted an amatoxin syndrome.
Testing for amatoxin was positive in urine and plasma samples in both patients, using
the enzyme-linked immunosorbent assay method. The testing confirmed that patients
consumed mushroom, mistaken for Boletus edulis, containing amatoxin (Figure 1). These
findings consolidated our diagnosis of amatoxin syndrome.
Figure 1
Photographs of the 2 mushroom species suspected to have been mingled by our patients.
(a) Edible Boletus edulis. (b−d) Young Amanita phalloides var. alba at 5 different
steps of its growth.
Intravenous hydration including saline solution and sodium bicarbonate was first administered.
The husband also received insulin and glucose, which normalized kalemia within 12
hours. Intravenous N-acetyl-cysteine was started on the first day of hospitalization
according to the following protocol: 150 mg/kg in 15 minutes, then 50 mg/kg in 4 hours,
then 100 mg/kg in 16 hours, and finally 150 mg/kg per day until normalization of transaminases.
Intravenous silymarin was administered according to poison center advice: 5 mg/kg
in 2 hours followed by perfusion of 5 mg/kg 4 times a day for 3 days.
The evolution of laboratory results is shown in Figure 2. Renal function continued
to decrease during 48 hours (creatinine 4.61 mg/dl for the husband and 2.65 mg/dl
for the wife). Transaminase levels first increased until the third day of hospitalization,
without hepatocellular insufficiency, and then decreased slowly. Hepatic function
was normal 7 days after the ingestion. Partial recovery of renal function was observed
in both patients (creatinine 2.97mg/dl for the husband and 1.72 mg/dl for the wife).
Eight days after the mushroom ingestion, the husband presented with severe renal deterioration
with oliguria. Creatinine rose to 10.6 mg/dl without hyperkalemia. Hemodialysis was
required, and, given the absence of renal recovery, a kidney biopsy was performed
1 month after ingestion, showing fibrosis in 70% of parenchyma and acute tubular necrosis
(Figure 3). Because of the unusual evolution in the case of the husband, we suspected
a co-intoxication with Cortinarius leading to an orellanine syndrome. Tests were performed
on a urine sample collected on the first day of hospitalization to assess for the
presence of orellanine toxins, but unfortunately, because of technical difficulties
in isolating the toxin, results were not conclusive. The wife recovered baseline renal
function, whereas the husband presented with chronic end-stage kidney failure requiring
chronic dialysis.
Figure 2
Evolution of laboratory results. (a) Husband. (b) Wife. ALAT, alanine aminotransferase;
ALP, alkaline phosphatase; ASAT, aspartate aminotransferase; GGT, γ-glutamyltransferase.
Figure 3
Kidney biopsy specimens from biopsy performed in the husband. (a) Masson’s trichrome
showing severe interstitial fibrosis, tubules with flattened epithelial cells, and
degenerated epithelial cells in the tubular lumen. (b) Periodic acid−Schiff stain
with dilated tubular lumen, and loss of brush border of flattened epithelial cells.
Discussion
Four toxidromes due to mushroom poisoning include kidney failure (Table 2).3, 4 Amatoxin
syndrome is the most usual intoxication. Toxicity is due to 2 cyclopeptides: phallotoxin,
which is not absorbed by the intestine and causes gastrointestinal symptoms; and amatoxin,
which inhibits RNA polymerase II, resulting in deficient protein synthesis and cell
death. Cells with a high metabolism are mainly affected: hepatocytes, cells of the
proximal tubules of the kidneys, and intestinal mucosa. Amatoxins are thermostable,
so cooking or freezing does not alter their toxicity. Clinical presentation starts
6 to 12 hours after mushroom ingestion. The first stage includes a cholera-like diarrhea,
vomiting, and abdominal pain. Thereafter, patients show clinical improvement. However,
cytolytic hepatitis occurs silently. Forty-eight hours or more after the ingestion,
the third phase begins, with severe hepatic failure and kidney failure. Ultimately,
the pancreas and nervous central system may be affected.5, 6 Orellanine syndrome is
due to Cortinarius, mushrooms found in Europe, Australia, and Japan. Orellanine inhibits
protein synthesis and generates free oxygen radicals, leading to tubulo-interstitial
nephritis. Clinical presentation starts with digestive symptoms (nausea, vomiting,
and diarrhea) and headache, anorexia, and chills within 24−36 hours after the mushroom
ingestion. Oliguric acute kidney failure appears 2 to 20 days afterward, evolving
toward terminal chronic kidney disease in 40% to 60% of patients.
4
Table 2
Characteristics of toxidromes associated with renal failure after mushroom poisoning
Toxidrome
Amatoxin syndromeGroup 1A
Early-onset renal failureGroup 1B
Orellanine syndromeGroup 1C
Rhabdomyolysis syndromeGroup 3A and 3B
Symptoms
GastroenteritisHepatic failureAcute renal failure
GastroenteritisAcute renal failure
GastroenteritisAcute renal failure
GastroenteritisMuscle painAcute renal failure
Onset of symptoms
Late onset toxicity (within 6–24 h)
Early-onset gastrointestinal toxicity (30 min–1 h)Late-onset renal toxicity (within
12–24 h)
Delayed-onset toxicity (within 3–20 days)
Rapid-onset myotoxicity (within 2 h) or delayed-onset toxicity (within 24–72 h)
Mechanism of renal toxicity
Inactivation of RNA polymerase II and inhibition of protein synthesis
Unknown
Interruption of production of adenosine triphosphate at proximal tubular brush border
Rhabdomyolysis
Mycotoxin
Cyclopeptides:- Amatoxin- Phallotoxin
Allenic norleucine
OrellanineCortinarin A and B
Cycloprop-2-ene carboxylic acidSaponaceolide B and M
Species
Amanita phalloides
Amanita verna
Amanita virosa
Lepiota helveola
Galerina marginata
Galerina autumnalis
Amanita smithiana
Amanita pseudoporphyria
Amanita proxima
Amanita gracilior
Amanita echinocephala
Cortinarius orellanus
Cortinarius speciosissinus
Tricholoma equestre
Tricholoma terreum
Russula subnigricans Leccinum spp.
Boletus spp.
Adapted by permission from White J, Weinstein SA, De Haro L, et al. Mushroom poisoning:
a proposed new clinical classification. Toxicon. 2019;157:53–65
3
and Springer Nature, Toxicological Reviews, New syndromes in mushroom poisoning, Saviuc
P, Danel V. Volume 25, pages 199–209. Copyright © 2006.
4
In the present cases, renal failure is the prominent feature, which is unusual in
mushroom poisoning. The onset of symptoms was too early to fit an orellanine syndrome,
and rhabdomyolysis was excluded because creatine phosphokinase levels were within
the normal range. The usual mushrooms responsible for an early-onset renal syndrome,
from the norleucine group, are not found in the North of France.
Patients with kidney failure secondary to fungal toxin ingestion can present with
leukocyturia (50%), hematuria (45.2%), and proteinuria (30.6%). Kidney biopsy shows
tubulo-interstitial nephritis with tubular necrosis, interstitial edema with inflammatory
infiltrates, and interstitial fibrosis.
7
Diagnosis is confirmed by finding the toxin in body fluids or tissues. Amatoxins can
be found in urine until 4 days after ingestion, in plasma in the first 36 hours, and
also in gastrointestinal fluids, feces, and tissues (liver and kidney).
8
Orellanine can be found in plasma and urine, but confirmation of orellanine intoxication
is difficult because of the latency of the symptoms. At the time that the diagnosis
is suspected, toxins are often undetectable in fluids. Nevertheless, toxins persist
several months in renal parenchyma. It has to be noted that the amatoxin concentration
does not correlate with the severity of poisoning.
9
Recently, White et al. proposed a new classification of mushroom poisoning. It is
divided into 6 groups, depending on the predominant clinical symptoms. Nevertheless,
diagnosis is often difficult because of atypical clinical presentation and frequent
co-ingestion of several types of mushrooms. In an American study, 86% of mushroom
exposure was of unknown varieties.
1
The easier way to identify the mushroom is to obtain a photograph of the picked mushrooms
and to show it to a skillful mycologist, but it is rarely available. That is why careful
questioning is important. The physician should try to find out where the mushroom
was picked and under which kind of tree, for how long and how it was stored, and how
it was cooked. Then, the delay and determination of the toxidrome should guide the
clinician. White et al. propose an algorithm divided into 6 sequential steps to help
the physician.
3
In the case of our patients, considering first the gastrointestinal symptoms would
lead us to the suspected diagnosis of amatoxin syndrome, whereas the diagnosis remains
“uncertain” when starting with the symptom abnormal renal function.
3
There is no uniformly accepted treatment protocol for mushroom poisoning. Use of activated
charcoal is controversial, as poisoned patients are usually asymptomatic several hours
after mushroom ingestion, and activated charcoal usually is useful only in the first
6 hours after ingestion. However, due to enterohepatic circulation of fungal toxins,
most authors recommend the administration of multiple-dose activated charcoal during
the first 3 days after ingestion. Supportive care includes rehydration and correction
of electrolytic abnormalities. Vomiting and diarrhea must be tolerated because they
allow the elimination of toxins.
No specific amatoxin antidote is available, but some therapeutic agents are useful.
Silymarin, a natural extract from milk thistle, contains silibinin, which inhibits
amatoxin uptake into the hepatocyte if given in the first 3 days after ingestion.
Silymarin should be administered with an i.v. loading dose of 5 mg/kg over 1 hour,
followed by a continuous i.v. infusion of 20 mg/kg per day for 3 to 6 days according
to transaminase level normalization. N-acetylcysteine, a glutathione precursor, has
a hepatoprotective effect. Other treatments such as i.v. benzylpenicillin, vitamin
C, and cimetidine have been used with less success in amanita poisoning. Recently,
a new treatment, polymixin B, showed promising results among animals by preventing
hepatic and renal damage and by increasing survival.
10
If the results are confirmed among patients, it might be an antidote for amatoxin
poisoning. Nowadays, the association of silymarin and N-acetylcysteine seems to be
the most effective therapy in amanita poisoning. Treatment should be started as soon
as possible. Fulminant hepatic failure sometimes requires liver transplantation.
9
No antidote is available for orellanine or allenic norleucine, and then treatment
is only supportive.
4
Renal prognosis is frequently poor, evolving toward end-stage renal disease requiring
chronic dialysis or kidney transplantation.
Hemodialysis is not effective to eliminate mycotoxins and is indicated only in the
case of severe acute kidney injury. Plasma exchanges and hemoperfusion have been used,
with a lack of efficacy, probably because mycotoxins quickly disappear from plasma.
7
The initial evolution of our 2 patients’ cases after treatment with NAC and silymarin
was positive, making us think that these treatments had been beneficial. Unfortunately,
kidney function worsened in a second step in the husband’s case. Renal injury was
severe, as assessed by histological analysis, with 70% of fibrosis in the renal parenchyma.
In conclusion, we expose here the cases of 2 married patients presenting with acute
tubular necrosis due to amatoxin poisoning, after ingestion of young Amanita phalloides
mistaken for Boletus edulis. These cases underline the difficulties in making the
diagnosis of mushroom poisoning and determining the exact species of mushroom concerned
(Table 3). Nephrologists should be aware of the main features of these life-threatening
poisonings, especially since an antidote is available and effective in certain cases,
depending on the responsible mushroom species.
Table 3
Teaching points
-
Early syndromes (<6 h) are usually associated with a good prognosis, whereas delayed
syndromes have poorer outcomes.
-
Four toxidromes due to mushroom poisoning include kidney failure: early-onset renal
failure, amatoxin syndrome, orellanine syndrome, and rhabdomyolysis syndrome.
-
Finding the specific mushroom species involved is mandatory, using careful questioning
and photographs, because specific treatment exists for some mushroom poisoning.
-
Amatoxins can be found in urine until 4 days after ingestion, in plasma in the first
36 h, and also in gastrointestinal fluids, feces, and tissues (liver and kidney).
-
Combined use of silymarin and N-acetyl-cysteine (NAC) seems to be the most effective
therapy in amanita poisoning and should be started as soon as possible.
Disclosure
All the authors declared no competing interests.